Specified Drug Use-Results Survey on "ACOALAN for CAD "

Specified Drug Use-Results Survey on "ACOALAN for CAD " - Specified Drug Use-Results Survey on "ACOALAN for CAD "

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050276

Enrollment

Registered

2023-02-08

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital antithrombin III deficiency (CAD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All CAD patients who received ACOALAN for tendency of thrombosis till the end of survey enrollment.

Exclusion criteria

Exclusion criteria: When the contract is not concluded When the number of contract cases has been reached If the administration start date is out of the contract period For already registered patients Patients used for diseases other than approved efficacy benefits

Design outcomes

Primary

Measure	Time frame
Safety 1.Development of ADR/infectious diseases (type, incident rate, etc.) 2.Investigation of factors considered to affect safety 3.Status of serious adverse events Effectiveness 1.Effective rate 2.Examination of factors considered to affect the effectiveness	—

Countries

Japan

Contacts

Public ContactShuji Horiguchi

Shuji Horiguchi Pharmacovigilance Division

umin_acoa.sb@kyowakirin.com03-5205-7200

Outcome results